OssDsign 대차 대조표 상태

재무 상태 기준 확인 6/6

OssDsign 의 총 주주 지분은 SEK214.4M 이고 총 부채는 SEK342.0K, 이는 부채 대 자기자본 비율을 0.2% 로 가져옵니다. 총자산과 총부채는 각각 SEK295.6M 및 SEK81.1M 입니다.

주요 정보

0.2%

부채 비율

SEK 342.00k

부채

이자 보상 비율	n/a
현금	SEK 108.94m
주식	SEK 214.45m
총 부채	SEK 81.11m
총 자산	SEK 295.56m

최근 재무 상태 업데이트

Recent updates

재무 상태 분석

단기부채: 5J6 의 단기 자산 ( SEK144.7M )이 단기 부채( SEK24.3M ).

장기 부채: 5J6 의 단기 자산( SEK144.7M )이 장기 부채( SEK56.8M ).

부채 대 자본 내역 및 분석

부채 수준: 5J6 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: 5J6 의 부채 대 자기자본 비율은 지난 5년간 1.8% 에서 0.2% 로 감소했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 5J6 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 2.1 %의 역사적 비율로 계속 감소한다면 5J6 ) 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

OssDsign 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

Recent updates

Third quarter 2024 earnings released: kr0.10 loss per share (vs kr0.50 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.30 loss in 2Q 2023)

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

Forecast breakeven date moved forward to 2024

Full year 2023 earnings released: kr1.60 loss per share (vs kr1.70 loss in FY 2022)

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Now 22% undervalued

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Forecast breakeven date moved forward to 2024

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

No longer forecast to breakeven

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.30 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.40 loss per share (vs kr0.40 loss in 2Q 2021)

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

First quarter 2022 earnings released: kr0.40 loss per share (vs kr1.10 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants

First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020)

Anders Svensson Joins OssDsign AB (Publ) as Chief Financial Officer

OssDsign AB (publ), Annual General Meeting, Jun 04, 2021

New 90-day low: €1.35

Full year 2020 earnings released: kr4.40 loss per share (vs kr5.46 loss in FY 2019)

Revenue misses expectations

OssDsign AB (publ) Announces New Clinical Data from 1,055 Cranioplasty Procedures

New 90-day low: €1.36

Chairman of the Board recently bought €26k worth of stock

Svensson's CFO Claes Lindblad Is Leaving the Company

Third quarter 2020 earnings released: kr1.10 loss per share

Revenue misses expectations

OssDsign AB (publ) to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.42

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.169392 million.

Earnings released

OssDsign AB (publ) Announces Chief Executive Officer Changes

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기